HEMOSTEMIX EXPANDS CLINICAL OPERATIONS WITH NEW PATIENT-CARE DIRECTOR
CALGARY, Alberta — December 4, 2025 — Hemostemix Inc., a leader in autologous stem-cell therapeutics, has appointed Shaune Harding,...
ACP-01
Advertisement
Sharp Therapeutics Advances Toward 2026 Clinical Trials
Pittsburgh, PA & Toronto, ON — November 26, 2025. Sharp Therapeutics Corp. has released its condensed interim consolidated financial...
Hemostemix Expands With First Cardiology Practice Acquisitions
CALGARY, Alberta — November 26, 2025. Hemostemix Inc. has taken a major step in its global clinical-commercial expansion, announcing...
ACP-01 Cell Therapy Moves Into Trial for Vascular Dementia
Calgary, Alberta — November 20, 2025 — Hemostemix Inc. announced that Dr. William R. Shankle, MS, MD, FACP, a...
Hemostemix Seeks Ethics Approval for Stem Cell Dementia Trial
CALGARY, Alberta, Oct. 9, 2025 — Hemostemix has filed for Institutional Review Board (IRB) approval of its Phase 1...
Advertisement
